Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome?

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 640-641

  Van Gelder, T ^a   Hesselink, D A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CYCLOSPORIN; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ALLELE; CLINICAL TRIAL; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952566293     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.42     Document Type: Note

References (10)

1. Meier-Kriesche H.U., et al. Immunosuppression: evolution in practice and trends 1994-2004. Am. J. Transplant. 6; 1111-1131 (2006).
2. Wallemacq, P. et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug. Monit. 31, 139-152 (2009).
3. Hesselink, D.A. et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003).
4. MacPhee, I.A. et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4, 914-919 (2004).
5. Thervet, E. et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721-726 (2010).
6. Hesselink, D.A. et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet. Genomics. 18, 339-348 (2008).
7. Evans, W.E. & Relling, M.V. Moving towards individualized medicine with pharmacogenomics. Nature. 429, 464-468 (2004).
8. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
9. Nankivell, B.J., Borrows, R.J., Fung, C.L., O'Connell, P.J., Chapman, J.R. & Allen, R.D. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 78, 557-565 (2004).
10. Naesens, M., Lerut, E., de Jonge, H., Van Damme, B., Vanrenterghem, Y. & Kuypers, DR. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20, 2468-2480 (2009).